<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37015258</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8227</ISSN><JournalIssue CitedMedium="Internet"><Volume>199</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Diabetes research and clinical practice</Title><ISOAbbreviation>Diabetes Res Clin Pract</ISOAbbreviation></Journal><ArticleTitle>Repurposing exercise training and pharmacological therapies to address the post-acute sequelae of COVID-19 (PASC) in diabetes mellitus.</ArticleTitle><Pagination><StartPage>110651</StartPage><MedlinePgn>110651</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.diabres.2023.110651</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-8227(23)00411-4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jie Chee</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Tan Tock Seng Hospital, Singapore. Electronic address: cheeyingjie_chee@ttsh.com.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalan</LastName><ForeName>Rinkoo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Tan Tock Seng Hospital, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University Singapore. Electronic address: rinkoo_dalan@ttsh.com.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Diabetes Res Clin Pract</MedlineTA><NlmUniqueID>8508335</NlmUniqueID><ISSNLinking>0168-8227</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37015258</ArticleId><ArticleId IdType="pmc">PMC10073874</ArticleId><ArticleId IdType="doi">10.1016/j.diabres.2023.110651</ArticleId><ArticleId IdType="pii">S0168-8227(23)00411-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10:311&#x2013;321. doi: 10.1016/S2213-8587(22)00044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding J.L., Oviedo S.A., Ali M.K., Ofotokun I., Gander J.C., Patel S.A., et al. The bidirectional association between diabetes and long-COVID-19 - A systematic review. Diabetes Res Clin Pract. 2023;195 doi: 10.1016/j.diabres.2022.110202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2022.110202</ArticleId><ArticleId IdType="pmc">PMC9727969</ArticleId><ArticleId IdType="pubmed">36496030</ArticleId></ArticleIdList></Reference><Reference><Citation>Marfella R., Sardu C., D'Onofrio N., Prattichizzo F., Scisciola L., Messina V., et al. Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nat Commun. 2022;13:2318. doi: 10.1038/s41467-022-30068-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30068-2</ArticleId><ArticleId IdType="pmc">PMC9051134</ArticleId><ArticleId IdType="pubmed">35484164</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell C.D., Lone N.I., Baillie J.K. Comorbidities, multimorbidity and COVID-19. Nat Med. 2023;29:334&#x2013;343. doi: 10.1038/s41591-022-02156-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02156-9</ArticleId><ArticleId IdType="pubmed">36797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld M.S., Sun K., Tahir P., Peluso M.J., Deeks S.G., Aras M.A., et al. Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-19 Symptoms in Adults: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5:e2236057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9557896</ArticleId><ArticleId IdType="pubmed">36223120</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh I., Joseph P., Heerdt P.M., Cullinan M., Lutchmansingh D.D., Gulati M., et al. Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. Chest. 2022;161:54&#x2013;63. doi: 10.1016/j.chest.2021.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.08.010</ArticleId><ArticleId IdType="pmc">PMC8354807</ArticleId><ArticleId IdType="pubmed">34389297</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer E., Petrache I., Goldstein N.M., Olin J.T., Keith R.C., Modena B., et al. Decreased Fatty Acid Oxidation and Altered Lactate Production during Exercise in Patients with Post-acute COVID-19 Syndrome. Am J Respir Crit Care Med. 2022;205:126&#x2013;129. doi: 10.1164/rccm.202108-1903LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202108-1903LE</ArticleId><ArticleId IdType="pmc">PMC8865580</ArticleId><ArticleId IdType="pubmed">34665688</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesti L., Pugliese N.R., Sciuto P., Natali A. Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovasc Diabetol. 2020;19:134. doi: 10.1186/s12933-020-01109-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01109-1</ArticleId><ArticleId IdType="pmc">PMC7487838</ArticleId><ArticleId IdType="pubmed">32891175</ArticleId></ArticleIdList></Reference><Reference><Citation>Astin R., Banerjee A., Baker M.R., Dani M., Ford E., Hull J.H., et al. Long COVID: mechanisms, risk factors and recovery. Exp Physiol. 2023;108:12&#x2013;27. doi: 10.1113/EP090802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/EP090802</ArticleId><ArticleId IdType="pmc">PMC10103775</ArticleId><ArticleId IdType="pubmed">36412084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesinovic J., Zengin A., De Courten B., Ebeling P.R., Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019;12:1057&#x2013;1072. doi: 10.2147/DMSO.S186600.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DMSO.S186600</ArticleId><ArticleId IdType="pmc">PMC6630094</ArticleId><ArticleId IdType="pubmed">31372016</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite S.A., Monk A.M., Upham P.A., Bergenstal R.M. Low cardiorespiratory fitness in people at risk for type 2 diabetes: early marker for insulin resistance. Diabetol Metab Syndr. 2009;1:8. doi: 10.1186/1758-5996-1-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1758-5996-1-8</ArticleId><ArticleId IdType="pmc">PMC2762992</ArticleId><ArticleId IdType="pubmed">19825145</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;zen T., Ba&#x15f;aran N.&#xc7;., T&#x131;nazl&#x131; M., &#xd6;z&#x131;&#x15f;&#x131;k L. Musculoskeletal problems in diabetes mellitus. Eur J Rheumatol. 2018;5:258&#x2013;265. doi: 10.5152/eurjrheum.2018.18044.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2018.18044</ArticleId><ArticleId IdType="pmc">PMC6267753</ArticleId><ArticleId IdType="pubmed">30388074</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudofker E.W., Parker H., Cornwell W.K., 3rd. An Exercise Prescription as a Novel Management Strategy for Treatment of Long COVID. JACC Case Rep. 2022;4:1344&#x2013;1347. doi: 10.1016/j.jaccas.2022.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccas.2022.06.026</ArticleId><ArticleId IdType="pmc">PMC9580598</ArticleId><ArticleId IdType="pubmed">36278147</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Shi H., Liu X., Sun T., Wu J., Liu Z. Effect of Pulmonary Rehabilitation for Patients With Post-COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2022;9 doi: 10.3389/fmed.2022.837420.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.837420</ArticleId><ArticleId IdType="pmc">PMC8899076</ArticleId><ArticleId IdType="pubmed">35265644</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C., Buse J.B., Liebovitz D., Nicklas J., Puskarich M., Cohen K.R., et al. Outpatient Treatment of COVID-19 and the Development of Long COVID Over 10 Months: A Multi-Center, Quadruple-Blind. Parallel Group Randomized Phase 3 Trial [Preprint] 2023 doi: 10.2139/ssrn.4375620.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4375620</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron A.R., Morrison V.L., Levin D., Mohan M., Forteath C., Beall C., et al. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016;119:652&#x2013;665. doi: 10.1161/CIRCRESAHA.116.308445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.308445</ArticleId><ArticleId IdType="pmc">PMC4990459</ArticleId><ArticleId IdType="pubmed">27418629</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-L&#xf3;pez C., Cervantes-Luevano K., Aguirre-S&#xe1;nchez J.S., Flores-Caballero J.C., Alvarez-Delgado C., Bernaldez-Sarabia J., et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind. Phase IIb clinical trial Biomed Pharmacother. 2022;152 doi: 10.1016/j.biopha.2022.113223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113223</ArticleId><ArticleId IdType="pmc">PMC9159967</ArticleId><ArticleId IdType="pubmed">35709650</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorrips S.N., Saucedo-Orozco H., S&#xe1;nchez-Aguilera P.I., De Boer R.A., Van der Meer P., Westenbrink B.D. Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure? Int J Mol Sci. 2022 Aug;3(23):8631. doi: 10.3390/ijms23158631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23158631</ArticleId><ArticleId IdType="pmc">PMC9369142</ArticleId><ArticleId IdType="pubmed">35955784</ArticleId></ArticleIdList></Reference><Reference><Citation>Berndt J., Ooi S.L., Pak S.C. What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?-A Mini Review. Molecules. 2021;26:4822. doi: 10.3390/molecules26164822.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26164822</ArticleId><ArticleId IdType="pmc">PMC8400553</ArticleId><ArticleId IdType="pubmed">34443410</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>